Related Experiment Video

Updated: May 9, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Adaptation to chronic mTOR inhibition in cancer and in aging

Rebecca Gilley1, Kathryn Balmanno, Claire L Cope

  • 1Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.

Biochemical Society Transactions
|July 19, 2013
PubMed

Insights

Tumor cells develop resistance to mammalian target of rapamycin (mTOR) inhibitors by adapting their signaling networks. Understanding these adaptations can reveal new strategies to enhance anticancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The mammalian target of rapamycin (mTOR) kinase regulates cell growth and metabolism, making it a key target in cancer therapy.
  • Existing mTORC1 inhibitors show limited efficacy; thus, ATP-competitive inhibitors targeting both mTORC1 and mTORC2 are under development.
  • Acquired resistance is a significant challenge for targeted kinase inhibitors, including those targeting mTOR.

Purpose of the Study:

  • To review the mechanisms by which tumor cells adapt and develop resistance to mTOR inhibitors.
  • To explore how understanding resistance pathways can inform combination therapies.
  • To contrast cancer cell resistance with lifespan extension observed in other organisms.

Main Methods:

  • Literature review of studies on tumor cell adaptation to mTOR inhibitors.
  • Analysis of signaling network remodeling in resistant cancer cells.
  • Comparison of cancer cell resistance mechanisms with effects of chronic mTOR inhibition on aging.

Main Results:

  • Tumor cells remodel signaling networks to bypass mTOR inhibition and sustain survival.
  • Specific downstream effector pathways are activated to promote proliferation despite mTOR blockade.
  • Resistance mechanisms in cancer differ from the beneficial effects of mTOR inhibition on lifespan in model organisms.

Conclusions:

  • Understanding tumor cell adaptation to mTOR inhibitors is crucial for developing effective anticancer strategies.
  • Identifying key resistance pathways can guide the design of combination therapies to overcome resistance.
  • Further research is needed to fully elucidate the complex interplay between mTOR signaling, cancer resistance, and aging.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...